Tonghua Golden-Horse Pharmaceutical Industry CoLtd 과거 수익 실적
과거 기준 확인 4/6
Tonghua Golden-Horse Pharmaceutical Industry CoLtd has been growing earnings at an average annual rate of 4%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 3.8% per year. Tonghua Golden-Horse Pharmaceutical Industry CoLtd's return on equity is 1.4%, and it has net margins of 2.2%.
주요 정보
4.0%
수익 성장률
-8.9%
EPS 성장률
Pharmaceuticals 산업 성장 | 10.9% |
매출 성장률 | 3.8% |
자기자본 수익률 | 1.4% |
순이익 | 2.2% |
최근 수익 업데이트 | 30 Sep 2023 |
최근 과거 실적 업데이트
Recent updates
Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd's (SZSE:000766) Popularity With Investors Is Under Threat From Overpricing
Aug 20Tonghua Golden-Horse Pharmaceutical Industry CoLtd (SZSE:000766) Seems To Use Debt Quite Sensibly
Jun 03Should You Be Adding Tonghua Golden-Horse Pharmaceutical Industry CoLtd (SZSE:000766) To Your Watchlist Today?
May 12Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (SZSE:000766) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected
Mar 06수익 및 비용 분석
Tonghua Golden-Horse Pharmaceutical Industry CoLtd 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
---|---|---|---|---|
30 Sep 23 | 1,501 | 33 | 939 | 70 |
30 Jun 23 | 1,506 | 33 | 935 | 68 |
31 Mar 23 | 1,422 | 31 | 880 | 66 |
31 Dec 22 | 1,471 | 30 | 920 | 65 |
30 Sep 22 | 1,446 | 32 | 905 | 71 |
30 Jun 22 | 1,424 | 20 | 918 | 75 |
31 Mar 22 | 1,490 | 37 | 956 | 69 |
01 Jan 22 | 1,515 | 35 | 983 | 64 |
30 Sep 21 | 1,425 | -185 | 1,186 | 37 |
30 Jun 21 | 1,448 | -263 | 1,291 | 37 |
31 Mar 21 | 1,343 | -311 | 1,287 | 45 |
31 Dec 20 | 1,112 | -359 | 1,174 | 50 |
30 Sep 20 | 1,344 | -2,359 | 1,251 | 54 |
30 Jun 20 | 1,509 | -2,234 | 1,276 | 74 |
31 Mar 20 | 1,719 | -2,137 | 1,378 | 72 |
31 Dec 19 | 1,977 | -2,042 | 1,502 | 67 |
30 Sep 19 | 2,126 | 310 | 1,476 | 73 |
30 Jun 19 | 2,151 | 310 | 1,492 | 68 |
31 Mar 19 | 2,144 | 323 | 1,465 | 68 |
31 Dec 18 | 2,095 | 331 | 1,402 | 67 |
30 Sep 18 | 1,982 | 263 | 1,250 | 66 |
30 Jun 18 | 1,824 | 272 | 1,093 | 66 |
31 Mar 18 | 1,684 | 257 | 952 | 55 |
31 Dec 17 | 1,521 | 258 | 833 | 52 |
30 Sep 17 | 1,239 | 254 | 607 | 23 |
30 Jun 17 | 1,088 | 246 | 492 | 0 |
31 Mar 17 | 918 | 222 | 384 | 0 |
31 Dec 16 | 850 | 213 | 347 | 0 |
30 Sep 16 | 578 | 134 | 245 | 0 |
30 Jun 16 | 427 | 90 | 185 | 0 |
31 Mar 16 | 283 | 40 | 138 | 0 |
31 Dec 15 | 198 | 7 | 118 | 0 |
30 Sep 15 | 197 | 6 | 112 | 0 |
30 Jun 15 | 207 | 4 | 130 | 0 |
31 Mar 15 | 205 | 3 | 129 | 0 |
31 Dec 14 | 208 | 5 | 127 | 0 |
30 Sep 14 | 198 | 6 | 123 | 0 |
30 Jun 14 | 175 | 8 | 109 | 0 |
31 Mar 14 | 164 | 15 | 97 | 0 |
31 Dec 13 | 148 | 4 | 95 | 0 |
양질의 수익: 000766 has high quality earnings.
이익 마진 증가: 000766's current net profit margins (2.2%) are higher than last year (2.2%).
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: 000766 has become profitable over the past 5 years.
성장 가속화: Insufficient data to compare 000766's past year earnings growth to its 5-year average.
수익 대 산업: 000766 earnings growth over the past year (4%) exceeded the Pharmaceuticals industry -1.2%.
자기자본 수익률
높은 ROE: 000766's Return on Equity (1.4%) is considered low.